Medical Research Network Growth leads to Senior Management Changes
Milton Keynes, UK. (1 September 2022) – MRN, a leading Clinical Trial Support Organization, today announced three significant Board level moves.
Since inception in 2006, MRN has seen dramatic and sustained organic international growth, with now over 330 employees, offices in UK, USA, Germany, Spain and Japan, delivering clinical trials in over 50 countries through the deployment of healthcare professionals and the integration of digital technology. This continued profitable, organic growth places MRN in a position to take the company further forward through an acquisitive strategy allowing diversification and strengthening the existing capabilities in key global markets.
To drive the development of MRN the following three C-Suite moves have been implemented, supporting both the focus on MRN Group development (inorganic growth) and drive core MRN organic growth:
- Graham Wylie moving from Chief Executive Officer to Executive Chairman – Graham will remain full time with the company, focusing on Corporate Strategic Development and Governance.
- Stuart Redding moving from Chief Operating Officer to Chief Executive Officer – Stuart has been with the company for all of its 16 years and has driven, at various times operations and business development. Stuart has a deep understanding of the organization and the market and will focus on the continued organic growth of the core MRN business
- Todd McGrath moving from Senior Vice President, Portfolio Delivery to Chief Operating Officer – Todd has been driving Project Management, for 7 years as Head of MRN Inc. Todd’s move into the COO role, will retain the continuity of leadership in the operating functions. Todd will focus on efficient delivery for MRN’s clients and integration of new services into MRN.
Graham Wylie said: “These changes will prepare MRN for our next phase, by making space for more senior management to lead the company and allow us to increase our various avenues of growth to maximize our position as one of the largest providers of these services around the globe.”
“I am delighted for both Stuart and Todd, who have shown themselves to excel in their previous roles within MRN. They will continue to deliver great things for our clients, staff, vendors, and investors. I am remaining with the company, that I founded and love, but am now focusing on our development as a much larger entity through inorganic growth”
MRN provides the market leading platforms for global implementation of decentralized clinical trials (DCT). Their Home Trial Support service takes clinical trial research visits to patients in their own community, wherever they live around the world. MRN’s innovative and creative in-home visit design supports patients, research sites, and drug developers by combining an integrated suite of clinical, personnel and digital/eClinical DCT elements, enhancing the delivery of clinical trials making them more flexible, efficient, and improving data quality.
At MRN we understand the complexities of today’s clinical trial environment and the burden placed on patients, clients, and sites. Our services are designed to ease these burdens, from community researchers, digital technology deployment, through to investigator site professional support; accelerating patient recruitment and retention with improved data quality. We work to maximize the efficiency of clinical trials for drug developers, by improving the patient’s experience, no matter where their community is in the world.
Medical Research Network
Vice President Commercial Development